-
June 25, 2021Elpiscience Announces CDE Clearance of IND Application for ES102 in Combination of Toripalimab
SHANGHAI/SUZHOU, China, June 25, 2021. Elpiscience Biopharma Ltd., a clinical-stage biotech company focusing on the discovery and development of next-generation cancer immunotherapies, today announced...
-
June 02, 2021Elpiscience to Present at the Jefferies 2021 Healthcare Conference
SHANGHAI/SUZHOU, China, June 2, 2021. Elpiscience Biopharma Ltd., a clinical stage biotech company focusing on the discovery and development of next-generation cancer immunotherapies, today announced ...
-
May 13, 2021Elpiscience Announces the Completion of $105 Million Series C Financing
SHANGHAI/SUZHOU, China, May 13, 2021. Elpiscience Biopharma, a clinical stage biopharma focusing on the discovery and development of next-generation cancer immunotherapies, announced today the cl...
-
January 20, 2021Elpiscience and TRIGR Announce an Exclusive License Agreement of TR009 in Greater China
1. Transaction to immediately accelerate clinical development of TR009 in Greater China and combine with Elpiscience’s deep pipeline of next generation immunotherapies； 2. TRIGR and Elpiscien...
-
January 11, 2021Elpiscience to Present at 39th Annual J.P. MORGAN Healthcare Conference
Shanghai, China, January 11, 2021. Elpiscience Biopharma Ltd., a clinical stage biotech company focusing on the discovery and development of next-generation cancer immunotherapies, today announce...
-
December 30, 2020Elpiscience was Named as One of the Cultivated Unicorn Enterprises of Suzhou
Shanghai/Suzhou, China, 30th December 2020. Elpiscience Biopharma Ltd., a clinical stage biotech company focusing on the discovery and development of next-generation cancer immunotherapies, was named ...
